The Enterprise Value as of November 2024 (TTM) for I-Mab (IMAB) is 448.84M

According to I-Mab’s latest financial reports and current stock price. The company's current Enterprise Value is 448.84M. This represents a change of -21.60% compared to the average of 572.52M of the last 4 quarters.

I-Mab (IMAB) Historical Enterprise Value (quarterly & annually)

How has IMAB Enterprise Value performed in the past?

The mean historical Enterprise Value of I-Mab over the last ten years is 4.85B. The current 448.84M Enterprise Value has changed 825.11% with respect to the historical average. Over the past ten years (40 quarters), IMAB's Enterprise Value was at its highest in in the June 2021 quarter at 35.49B. The Enterprise Value was at its lowest in in the September 2023 quarter at -1286470415.83.

I-Mab (IMAB) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of I-Mab Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

I-Mab (IMAB) Average Enterprise Value

How has IMAB Enterprise Value performed in the past?

The current Enterprise Value of I-Mab (IMAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

I-Mab (IMAB) Enterprise Value vs. Peers

How is IMAB’s Enterprise Value compared to its peers?

I-Mab’s Enterprise Value is less than BeiGene, Ltd. (19.75B), less than Krystal Biotech, Inc. (5.10B), less than Immunovant, Inc. (3.47B), less than Mirati Therapeutics, Inc. (3.91B), greater than Foghorn Therapeutics Inc. (417.24M), greater than Shattuck Labs, Inc. (6.89M), greater than Monte Rosa Therapeutics, Inc. (439.72M), less than Kymera Therapeutics, Inc. (2.89B), less than Nurix Therapeutics, Inc. (1.49B), greater than Lyell Immunopharma, Inc. (216.40M), less than Cullinan Oncology, Inc. (630.54M), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (9.43B), less than Gracell Biotechnologies Inc. (5.61B), greater than Design Therapeutics, Inc. (290.40M), less than Erasca, Inc. (747.42M), less than Ascendis Pharma A/S (7.61B), less than Apellis Pharmaceuticals, Inc. (3.90B), less than Akero Therapeutics, Inc. (2.00B), less than Blueprint Medicines Corporation (6.36B),

Build a custom stock screener for I-Mab (IMAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like I-Mab using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

I-Mab (IMAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like I-Mab or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.